Novavax Q3 2022 Financial Results and Operational Highlights

Novavax presents third quarter 2022 financial results and operational updates as of November 8, 2022. The presentation details the company's progress on NVX-CoV2373, a COVID-19 vaccine candidate, alongside strategic priorities, financial guidance, and global supply chain readiness. Key focus areas include regulatory submissions, manufacturing capacity expansion, and market opportunities for primary, booster, and pediatric vaccinations.